on behalf of the GEM (Grupo Español de MM)/PETHEMA (Programa para el Estudio de la Terapéutica en Hemopatías Malignas) cooperative study group Knowledge about clonal diversity and selection is critical to understand multiple myeloma (MM) pathogenesis, chemoresistance and progression. If targeted therapy becomes reality, identification and monitoring of intraclonal plasma cell (PC) heterogeneity would become increasingly demanded. Here we investigated the kinetics of intraclonal heterogeneity among 116 MM patients using 23-marker multidimensional flow cytometry (MFC) and principal component analysis, at diagnosis and during minimal residual disease (MRD) monitoring. Distinct phenotypic subclones were observed in 35/116 (30%) newly diagnosed MM patients. In 10/35 patients, persistent MRD was detected after 9 induction cycles, and longitudinal comparison of patient-paired diagnostic vs MRD samples unraveled phenotypic clonal tiding after therapy in half (5/10) of the patients. After demonstrating selection of distinct phenotypic subsets by therapeutic pressure, we investigated whether distinct fluorescence-activated cell-sorted PC subclones had different clonogenic and cytogenetic profiles. In half (5/10) of the patients analyzed, distinct phenotypic subclones showed different clonogenic potential when co-cultured with stromal cells, and in 6/11 cases distinct phenotypic subclones displayed unique cytogenetic profiles by interphase fluorescence in situ hybridization, including selective del(17p13). Collectively, we unravel potential therapeutic selection of preexisting diagnostic phenotypic subclones during MRD monitoring; because phenotypically distinct PCs may show different clonogenic and cytogenetic profiles, identification and follow-up of unique phenotypic-genetic myeloma PC subclones may become relevant for tailored therapy.
INTRODUCTION
The discovery and clinical incorporation of drugs with new mechanisms of action has led to high response rates in multiple myeloma (MM) patients. 1, 2 Albeit the better quality and significantly prolonged duration of response achieved after therapy, the vast majority of patients ultimately relapse; 3 thereafter, overall survival will mostly depend on the sensitivity of residual/resistant myeloma plasma cells (PCs) to salvage therapy. Such observations indicate that, while the majority of tumor cells are initially chemosensitive, a minimum number would be chemoresistant and responsible for tumor regrowth after variable periods of time, frequently in the absence of response to new lines of therapy. 4 Altogether, these findings point out to the existence of different subsets of myeloma PCs with unique patterns of chemoresistance. Accordingly, intratumoral genetic heterogeneity has not only been recently demonstrated in newly diagnosed MM patients [5] [6] [7] [8] [9] but also at relapse, where the subclonal diversity of myeloma PCs often differs to that observed at diagnosis. [4] [5] [6] 10, 11 However, no information exists on the subclonal distribution of myeloma PCs after response to first-line therapy where, particularly among patients in serological response, only low levels of minimal residual disease (MRD) tumor cells persist.
Multidimensional flow cytometry (MFC) is a readily available method to identify clonal PCs through aberrant antigenic expression profiles, 12 even when these are present in low numbers (that is, MRD). Furthermore, MFC has the advantage that myeloma PCs can be sorted according to their specific phenotypic profiles, which allows the possibility to perform additional studies on highly purified tumor PCs. Based on all the above, MFC could represent a useful technique to identify in individual patients distinct phenotypic myeloma PC subclones potentially coexisting at diagnosis and during MRD monitoring.
Here we used MFC to analyze intratumoral phenotypic heterogeneity in a series of 116 newly diagnosed MM patients. Additionally, we evaluated in vivo drug sensitivity of distinct phenotypic myeloma PC subclones coexisting in individual patients at diagnosis, through the phenotypic analysis of longitudinal patient-paired diagnostic vs MRD samples. Finally, we demonstrated that distinct phenotypic myeloma PC subclones often display different cytogenetic profiles and clonogenic potential.
MATERIALS AND METHODS

MFC immunophenotyping
Approximately 400 μl of EDTA-anticoagulated bone marrow (BM)-aspirated samples from 116 newly diagnosed MM patients included in the GEM2010 trial were immunophenotyped using an eight-color direct immunofluorescence stain-and-then-lyse technique, with four different combinations of monoclonal antibodies (MoAb): (Pacific Blue (PacB), Pacific Orange (PacO), fluorescein isothiocyanate (FITC), phycoerythrin (PE), peridinin chlorophyll protein-cyanin 5.5 (PerCP-Cy5.5), PE-cyanin 7 (PE-Cy7), allophycocyanin (APC), alexafluor 700 (AF700)): (i) CD29, CD45, CD11a, β7, CD79b, CD49d, CD19, CD38; (ii) CD11c, CD45, CD41a, CD49e, CD33, CD117, CD19, CD38; (iii) CD20, CD45, CD81, CD54, CD138, CD56, CD19, CD38; and (iv) HLA-DR, CD45, CD44, CXCR4, CD27, CD28, CD19, CD38. For the remaining MM patients (n = 18), a simplified immunophenotypic BM screening was performed following the EuroFlow guidelines and antibody panels. 13 Data acquisition was performed for approximately 10 6 leukocytes/tube in a FACSCantoII flow cytometer (Becton Dickinson Biosciences (BDB), San Jose, CA, USA) using the FACSDiva 6.1 software (BDB). Monitoring of instrument performance was performed daily using the Cytometer Setup Tracking (CST; BDB) and rainbow eight-peak beads (Spherotech, Inc.; Lake Forest, IL, USA) after laser stabilization, following the EuroFlow guidelines; 14 sample acquisition was performed only in case of longitudinal instrument stability. Per protocol, newly diagnosed MM patients included in the GEM2010-MAS65 trial (which investigates sequential chemotherapy with 9 cycles of bortezomib, melphalan, prednisone (VMP) followed by 9 cycles of lenalidomide, low-dose dexamethasone (Rd) (n = 56), vs alternating cycles of VMP and Rd up to 18 cycles (n = 60)) had BM samples studied after 9 induction cycles to monitor MRD levels; whenever persistent myeloma PCs were detected (MRD-positive), exactly the same immunophenotypic method performed at diagnosis was repeated for the characterization of the chemoresistant clone after therapy. In all patients, samples were collected after informed consent was given by each individual, according to the local ethical committees and the Helsinki Declaration protocol.
Generation of immunophenotypic protein expression profiles (iPEPs) to assess the intratumoral PC architecture
To generate iPEPs, we used first those five parameters measured in common use for each sample aliquot (CD38, CD45, CD19, forward light scatter (FSC) and sideward light scatter (SSC) to define the PC compartment. Then the merge function of the Infinicyt software (Cytognos SL, Salamanca, Spain) was used to fuse the different data files corresponding to the four different eightcolor MoAb combinations studied per sample into a single data file containing all the information measured for that sample. 15 For any single cell in each eight-color MoAb combination, this included data about those antigens that were measured directly on it and antigens that were not evaluated directly ('missing values') for that cell in the corresponding tube it was contained in. Then the calculation function of the Infinicyt software was used to fill in those 'missing values', based on the 'nearest neighbor' statistical principle, defined by its unique position in the multidimensional space created by the five common (backbone) parameters (FSC, SSC, CD38, CD45 and CD19). Ultimately, an iPEP was generated for every single PC, which included all 23 phenotypic markers analyzed plus FSC and SSC as illustrated in Figures 1b and c. 14 Finally, BM clonal PCs were discriminated from normal PCs based on their aberrant phenotypic profiles as extensively described elsewhere. 12 Intraclonal heterogeneity within the tumor PC Interphase fluorescence in situ hybridization (iFISH) studies on phenotypic distinct myeloma PC subclones Phenotypically distinct myeloma PC subclones from 11 MM patients were FACS (fluorescence-activated cell sorter)-sorted (FACSAria II, BDB; purity ⩾ 97%) to investigate their specific cytogenetic profiles. FACS-sorted PC subclones were fixed in 3/1 methanol/acetic (v/v) and screened by iFISH for the presence of immunoglobulin heavy chain translocations (t(4;14), t(11;14) and t(14;16)), del(13q14), del(17p13) and 1p/1q chromosomal alterations. A BX60 fluorescence microscope (Olympus, Hamburg, Germany) equipped with a × 100 oil objective was used for the enumeration of hybridization spots per nuclei. A minimum of 100 interphase nuclei were analyzed per probe/probe combination, as described elsewhere. 16 Only those spots with a similar size, intensity and shape were counted in areas with o1% unhybridized cells; doublet signals were considered as single spots. Deletion was defined by the loss of 1 or 2 fluorescence signals, whereas trisomy or hiperdiploidy was defined by gains of ⩾ 1 fluorescence signals, each one in ⩾ 10% of the nuclei. Immunoglobulin heavy chain translocations were considered as positive if present in ⩾ 10% of the nuclei.
Colony assays
Identical numbers of cells from two coexisting phenotypically distinct myeloma PC subclones from 10 patients with MM were FACS-sorted (FACSAria II, BDB; purity ⩾ 97%) and plated into Methocult media (StemCell Technologies, Grenoble, France) supplemented with 10% lymphocyte conditioned media plus 20 ng/ml interleukin-6 (Peprotech, London, UK) and 20 ng/ml IGF-1 (Prospec, Rehovot, Israel) and co-cultured with the human mesenchymal stem cell line immortalized by expression of the telomerase reverse transcriptase gene, hMSC-TERT (kindly provided by Dr Dario Campana, Department of Oncology and Pathology, St Jude Children's Research Hospital, Memphis, TN, USA), at a 10:1 ratio. Cells were cultured at 37°C in a 5% CO 2 humidified atmosphere. After 14 days of culture, colonies (⩾40 cells) and clusters (10-39 cells) were scored. As a negative control, the hMSC-TERT cell line alone was incubated under identical conditions, such control systematically showing no colonies or clusters at day +14 in the 10 experiments performed. Although the panel of MoAb covered a wide range of proteins, including integrins, adhesion molecules, activation and maturation-related markers, it should be noted that the topthree markers which contributed the most to dissect PC intratumoral heterogeneity were CD56, CD27 and CD81, all these markers being consensually used to screen for clonal PCs at baseline and MRD stages. Other relevant markers are listed in Figure 1e , and detailed description of the intratumoral composition on each of the 35 patients is shown in Supplementary Table S1 .
RESULTS
Intratumoral phenotypic heterogeneity in MM
Distinct phenotypic myeloma PC subclones show different chemoresistant profile
In order to evaluate the in vivo chemoresistant profile of different phenotypic subclones of myeloma PCs coexisting in a patient, we performed longitudinal comparisons between the diagnostic (baseline) tumor subclones and the chemoresistant myeloma PCs that persisted after treatment (MRD+) in patients who showed baseline phenotypic heterogeneity at the intratumoral myeloma PC level ( Figure 2 ). From the initial 116 cases included in the GEM2010 trial, 35 had 41 phenotypic subclone at diagnosis and therefore qualified for the present sub-analysis. In 10 of these 35 cases, persistent MRD was detected after nine cycles of treatment, and the iPEP of MRD clonal PCs was determined in these cases.
After merging the iPEP of baseline vs MRD myeloma PCs, we noted that in 5 of the 10 patients chemoresistant MRD cells scattered throughout the whole baseline tumor bulk (Figures 2a-e ); by contrast, in the other five patients clonal selection upon therapeutic pressure was observed, with MRD myeloma PCs clustering within specific baseline subclones (Figures 2f-j). For example, in one patient (97832; Figure 2h ) showing a predominant (CD33 het /CD56 + ) and a minor clone (CD33 + /CD56 − ) only the former persisted after nine cycles of alternating Rd-VMP; by contrast, in another case (99140; Figure 2j ) it was the minor clone present at diagnosis (CD27 + /CD138 + ) that remained after chemotherapy. These results demonstrate that distinct phenotypic myeloma PC subclones coexisting in individual patients at diagnosis frequently harbor specific chemoresistant profiles.
Distinct phenotypic myeloma PC subclones show different clonogenic potential The coexistence of distinct phenotypic myeloma PC subclones with different chemoresistant profiles prompted us to investigate whether such phenotypic subclones could also harbor different clonogenic potential. For this purpose, identical numbers (⩽500 000) of FACS-sorted distinct myeloma PC subsets from 10 patients were cultured with hTERT stromal cells. In 8 of the 10 cases, colonies and/or clusters were observed after 14 days of culture (Table 1) , and in 5 of these 8 patients (cases 105321, 107234, 109027, 112061 and 114053), one phenotypic subclone of myeloma PCs had greater than threefold more clonogenic potential than its paired myeloma PC subset. Minor differences were observed for patients 106344 (6 clusters for CD45 + subclone vs 3 clusters for CD45 − subclone) and 110803 (2 clusters for CD81 + subclone vs 4 clusters for CD81 − subclone), whereas virtually the same clonogenic potential was found for the two phenotypic subclones from patient 115085 (36 colonies for CD117 + subclone vs 35 colonies for CD117 − subclone). Noteworthy, no clear association was found between the pattern of expression of specific markers and an increased or decreased clonogenic potential; for example, tumor growth of myeloma PCs from patient 105321 ( Figure 3a) was apparently restricted to the FACS-sorted CD45 + subset, whereas in patient 107234 ( Figure 3b ) the clonogenic potential of CD45 + tumor cells was threefold inferior than that of the CD45 − subclone. investigate whether such phenotypic subsets also showed different genetic profiles. Using iFISH, we observed that in 6 out of 11 patients studied there was ⩾1 cytogenetic alteration present in one of the FACS-sorted myeloma PC subsets while being absent in the other (cases 100644, 100172, 381155, 380486, 113919, 114661; Table 2 ). In patient 100172 ( Figure 4a ) the β7 + and β7 − clonal PC subsets were both diploid for 1p, had gains at 1q and harbored a t(14q32); by contrast, del(13q14) and del(17p13) were detected in 78% and 11% of β7 − cells, respectively, but undetectable in β7 + cells. In patient 380486 (Figure 4b ), the CD56 + and CD56 − myeloma PC subsets had both trisomy of chromosome 1, del(14q32) and del(13q14); conversely, del(17p13) was observed in 60% of CD56 + myeloma PCs, while undetectable in the CD56 − subset. In fact, selective deletion of 17p13 in only one of the two FACS-sorted clonal PC subsets was observed in 4/5 cases carrying this alteration ( Table 2) .
DISCUSSION
The field of MM is experiencing unprecedented and exciting years of research and development. The existence of genetically defined patient subgroups with high-risk disease is well established, 17, 18 and continuous efforts are currently being taken to identify therapeutic strategies to overcome the adverse prognosis of these genetic subsets. 19 Moreover, clonal heterogeneity reinforces the need for targeted therapies designed to eradicate all potentially coexisting subclones in an individual patient. Overall, this requires accurate and readily available technology in order to identify, characterize and monitor such coexisting tumor subclones. 20 Here we used new 23-marker MFC to investigate in depth the phenotypic diversity of myeloma PCs in individual patients. Additionally, we showed the effect of first-line therapy on clonal selection by looking at MRD cells, unraveling the existence of truly primary chemoresistant phenotypic subclones within the whole population of myeloma PCs. Finally, we demonstrated that different phenotypic myeloma PC subclones may frequently show unique cytogenetic and clonogenic features.
After early observations 5,6,9 on individual and/or relatively small patient series by iFISH, copy-number variation analysis or whole genome sequencing showing the coexistence of multiple (~3) genetic subclones in newly diagnosed MM patients, Lohr et al. 10 and Bolli et al. 4 have recently confirmed and expanded on pivotal mutation analysis 21 through integrated mutational, copy number alteration and loss of heterozygosity profiles of PCs from large series of MM patients. Similar to previous observations, the latter authors confirmed that most patients harbored ⩾ 3 detectable genetic subclones (beyond the major clone), some patients having as many as seven subclones. 10 That notwithstanding, it should be noted that MM intraclonal heterogeneity had been inferred for many years using less sophisticated and more readily available techniques such as the serum free light-chains (the free light-chain escape phenomenon) 22 or iFISH. 23 In fact, both Keats et al. 6 and Schmidt-Hieber et al. 23 had shown that by iFISH it was possible to determine the relative distribution of different subclones of myeloma PCs coexisting in individual patients at diagnosis and/ or after disease progression. Of note, we and others have previously shown that some specific cytogenetic alterations were associated with the presence of unique antigenic profiles (for example, CD20, CD28 or CD117); 24-28 however, none of these studies postulated if intraclonal heterogeneity was behind this correlation.
The multiparameter nature of flow cytometry (MFC) allows the measurement of several proteins (antigens) inside and on the surface of thousands to millions of single cells per sample. Thus MFC provides specific information about individual PCs that allows clear discrimination between normal/reactive and myeloma PCs, even when these are present at very low numbers (for example, monoclonal gammopathy of unknown significance or MRD patient samples). Here we used the new analytic tools developed by the EuroFlow Consortium 14 to determine the iPEP of BM myeloma PCs and to investigate on phenotypic grounds the intraclonal heterogeneity of myeloma PCs from individual patients. Using operator-independent PCA-based tools, we showed that clonal diversity is observed in around one-third of a large series of 116 newly diagnosed MM patients. Because we are looking at the (surface) protein level, clonal heterogeneity by MFC was less frequently detected than previously reported by genomic techniques; conversely, the sensitivity of MFC to monitor and detect MRD is an advantage to perform on individual patients longitudinal comparisons between clonal diversity at diagnosis and MRD. Accordingly, in the present study we showed for the first time that therapeutic pressure over ⩾ 2 diagnostic phenotypic subclones frequently leads to in vivo selection of primary chemoresistant myeloma PCs (that is, MRD). Because of the limited number of patients, it was not possible to fully address whether such therapeutic pressure was more evident with sequential vs alterning chemotherapy; further investigations to fully address this question are now warranted. Other important aspect of MFC is the possibility to sort distinct clonal PC subsets according to patient-specific iPEPs and perform additional studies on such highly purified myeloma PC subpopulations. Using the latter applicability, we showed that distinct phenotypic subclones display different clonogenic potential. However, it should be noted that, despite quantitative differences, in many patients the clonogenic potential was not restricted to a single phenotypic subclone, supporting the concept that different tumor cell populations could harbor the capacity to self-renew. [29] [30] [31] Moreover, the colony efficacy observed herein (4/10 patients) is in line with previously reported data on primary MM cells 32, 33 and suggests that truly clonogenic cells in MM would constitute a minor population within the tumor bulk. The different functional behavior of coexisting phenotypic subclones prompted us to investigate whether such subclones could also harbor different genetic alterations. Interestingly, we found that in approximately half of the patients coexisting myeloma PC subsets defined by the presence vs absence of specific antigens may also show different cytogenetic profiles. Importantly, some of the cytogenetic alterations that were unequally distributed among distinct phenotypic myeloma PC subclones define patients with high-risk disease (for example, del (17p13)), and depending whether one looks to overall populations of CD138 + sorted PCs or to FACS-sorted myeloma PC subclones, a given patient may have different percentages of PCs carrying a specific cytogenetic abnormality or, most importantly, be classified as negative vs positive depending on the relative frequency of the coexisting myeloma PC subclones (Figure 4b ). Furthermore, one could hypothesize that, similarly to chronic lymphocytic leukemia, also in MM small subclones with TP53 deletion identified before treatment may become the predominant population at relapse 34 and hence influence the prognosis (although their initial low frequency). 35 Whether or not these small subclones are also primary chemoresistant and predominant in between disease diagnosis and relapse (that is, MRD) remains to be determined; however, if this happens to occur, it could perhaps change our perception on how to monitor patients' residual disease after initial chemotherapy. Thus these observations suggest that monitoring of MM patients could benefit from a more comprehensive approach that, on top of the quantification of the minor MRD clones, also informs on their cytogenetic Figure 4 . Distinct phenotypic myeloma PC subclones show different cytogenetic profiles. (a) FACS-sorted β7+ and β7 − subclones from patient 100172 were hybridized with probes for t(14q32) (red-green spots; left panel), 1q25 and 1p36 (green and red spots, respectively; middle panel), as well as 13q14 and 17p13 (green and red spots, respectively; right panel). The percentage of altered nuclei is indicated for each probe and myeloma PC subclone; probes with a diploid pattern were classified as 2N. (b) FACS-sorted CD56 + and CD56 − subclones from patient 380486 were hybridized with probes for t(14q32) (red-green spots; left panel) chromosomal regions, 13q14 (red spots; middle panel) and 17p13 (red spots; right panel). The percentage of altered nuclei is indicated for each probe and myeloma PC subclone; probes with a diploid pattern were classified as 2N.
Phenotypic characterization of MM clonal diversity background based on the information collected at diagnosis. Of note, the most informative markers to dissect PC intraclonal heterogeneity were CD56, CD27 and CD81, all of which are consensually used to screen for PC clonality at baseline, as well as at the MRD stage. Consequently, the methodology reported here could be implemented in routine practice without additional efforts.
In summary, in this study we demonstrate the phenotypic subclonal diversity within tumor PCs from individual MM patients, such subclones also carrying frequently different cytogenetic and functional profiles. As the balance between the different phenotypic subclones may fluctuate during the course of the disease (for example, in the setting of persistent MRD), the same could also be true to the predominance vs disappearance of specific genetic alterations (for example, del(17p13)) and the patients' risk of relapsefree survival. Thus cytogenetic characterization of myeloma PC phenotypic subclones easily recognizable at diagnosis and their subsequent monitoring after therapy may contribute to better tailor treatment and overcome chemoresistance in MM. Larger cooperative studies are now warranted to confirm such hypothesis.
